The Impact of Adipose Tissue on Insulin Resistance in Acromegaly

Trends in Endocrinology and Metabolism

Volumn 27, Issue 4, 2016, Pages 226-237

  Olarescu, Nicoleta Cristina ^a,b   Bollerslev, Jens ^a,b  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

Author keywords

Adipogenesis; Adipokines; Free fatty acids; Growth hormone; Inflammation; Insulin like growth factor I; Treatment

Indexed keywords

ADENYLATE CYCLASE; ADIPOCYTOKINE; ADIPONECTIN; ANGIOPEPTIN; CHEMERIN; FATTY ACID; FATTY ACID SYNTHASE; FIBROBLAST GROWTH FACTOR 21; GLUCOSE; GLYCOGEN; GROWTH HORMONE; INSULIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; LIPOPROTEIN LIPASE; MONOCYTE CHEMOTACTIC PROTEIN 1; OCTREOTIDE; OMENTIN 1; PASIREOTIDE; PEGVISOMANT; PROTEIN KINASE C; PYRUVATE DEHYDROGENASE COMPLEX; RESISTIN; RETINOBLASTOMA BINDING PROTEIN 4; SOMATOMEDIN C; SOMATOSTATIN RECEPTOR; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VASPIN;

ABDOMINAL OBESITY; ACROMEGALY; ADIPOCYTE; ADIPOGENESIS; ADIPOSE TISSUE; ANGIOGENESIS; AUTOCRINE EFFECT; BODY COMPOSITION; BODY FAT; CELL DIFFERENTIATION; CYTOKINE RELEASE; DIABETES MELLITUS; ENDOCRINE FUNCTION; EXTRACELLULAR MATRIX; GLUCAGON RELEASE; GLUCONEOGENESIS; GLUCOSE METABOLISM; GLUCOSE TRANSPORT; GLYCEMIC CONTROL; GLYCOGEN SYNTHESIS; GLYCOGENOLYSIS; GROWTH HORMONE RELEASE; HOMEOSTASIS; HUMAN; INFLAMMATORY CELL; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN SENSITIVITY; INTRAABDOMINAL FAT; KETOGENESIS; LIPID OXIDATION; LIPID STORAGE; LIPID TRANSPORT; LIPOGENESIS; LIPOLYSIS; LIPOTOXICITY; MACROPHAGE; MEDIATOR RELEASE; METABOLIC SYNDROME X; NONHUMAN; PANCREAS ISLET BETA CELL; PARACRINE SIGNALING; PRIORITY JOURNAL; REVIEW; SKELETAL MUSCLE; SUBCUTANEOUS FAT; INFLAMMATION; METABOLISM; PATHOPHYSIOLOGY; SECRETION (PROCESS); SIGNAL TRANSDUCTION;

ACROMEGALY; ADIPOGENESIS; ADIPOKINES; ADIPOSE TISSUE; DIABETES MELLITUS; GROWTH HORMONE; HUMANS; INFLAMMATION; INSULIN; INSULIN RESISTANCE; INSULIN-LIKE GROWTH FACTOR I; SIGNAL TRANSDUCTION;

EID: 84959377814     PISSN: 10432760     EISSN: 18793061     Source Type: Journal    
DOI: 10.1016/j.tem.2016.02.005     Document Type: Review

References (87)

1. Vega G.L., et al. Influence of body fat content and distribution on variation in metabolic risk. J. Clin. Endocrinol. Metab. 2006, 91:4459-4466.
2. Fieffe S., et al. Diabetes in acromegaly, prevalence, risk factors, and evolution: data from the French Acromegaly Registry. Eur. J. Endocrinol. 2011, 164:877-884.
3. Katznelson L., et al. Acromegaly: an endocrine society clinical practice guideline. J. Clin. Endocrinol. Metab. 2014, 99:3933-3951.
4. Olarescu N.C., et al. Adipocytes as a source of increased circulating levels of nicotinamide phosphoribosyltransferase/visfatin in active acromegaly. J. Clin. Endocrinol. Metab. 2012, 97:1355-1362.
5. Moller N., Jorgensen J.O. Effects of growth hormone on glucose, lipid, and protein metabolism in human subjects. Endocr. Rev. 2009, 30:152-177.
6. Saltiel A.R., Kahn C.R. Insulin signalling and the regulation of glucose and lipid metabolism. Nature 2001, 414:799-806.
7. Rosen E.D., Spiegelman B.M. What we talk about when we talk about fat. Cell 2014, 156:20-44.
8. Lafontan M. Adipose tissue and adipocyte dysregulation. Diabetes Metab. 2014, 40:16-28.
9. Defronzo R.A. Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes 2009, 58:773-795.
10. Gustafson B., et al. Insulin resistance and impaired adipogenesis. Trends Endocrinol. Metab. 2015, 26:193-200.
11. Fisker S., et al. Gene expression of the GH receptor in subcutaneous and intraabdominal fat in healthy females: relationship to GH-binding protein. Eur. J. Endocrinol. 2004, 150:773-777.
12. Nielsen C., et al. Growth hormone signaling in vivo in human muscle and adipose tissue: impact of insulin, substrate background, and growth hormone receptor blockade. J. Clin. Endocrinol. Metab. 2008, 93:2842-2850.
13. Vendelbo M.H., et al. GH signaling in human adipose and muscle tissue during 'feast and famine': amplification of exercise stimulation following fasting compared to glucose administration. Eur. J. Endocrinol. 2015, 173:283-290.
14. Richard A.J., Stephens J.M. Emerging roles of JAK-STAT signaling pathways in adipocytes. Trends Endocrinol. Metab. 2011, 22:325-332.
15. Samuel V.T., Shulman G.I. The pathogenesis of insulin resistance: integrating signaling pathways and substrate flux. J. Clin. Investig. 2016, 126:12-22.
16. Kahn S.E., et al. Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future. Lancet 2014, 383:1068-1083.
17. Gregor M.F., Hotamisligil G.S. Inflammatory mechanisms in obesity. Ann. Rev. Immunol. 2011, 29:415-445.
18. Palmer A.K., et al. Cellular senescence in type 2 diabetes: a therapeutic opportunity. Diabetes 2015, 64:2289-2298.
19. Odegaard J.I., Chawla A. Pleiotropic actions of insulin resistance and inflammation in metabolic homeostasis. Science 2013, 339:172-177.
20. Nguyen M.T., et al. A subpopulation of macrophages infiltrates hypertrophic adipose tissue and is activated by free fatty acids via Toll-like receptors 2 and 4 and JNK-dependent pathways. J. Biol. Chem. 2007, 282:35279-35292.
21. Boni-Schnetzler M., et al. Free fatty acids induce a proinflammatory response in islets via the abundantly expressed interleukin-1 receptor I. Endocrinology 2009, 150:5218-5229.
22. Yeop Han C., et al. Differential effect of saturated and unsaturated free fatty acids on the generation of monocyte adhesion and chemotactic factors by adipocytes: dissociation of adipocyte hypertrophy from inflammation. Diabetes 2010, 59:386-396.
23. Pal D., et al. Fetuin-A acts as an endogenous ligand of TLR4 to promote lipid-induced insulin resistance. Nat. Med. 2012, 18:1279-1285.
24. Donath M.Y. Targeting inflammation in the treatment of type 2 diabetes: time to start. Nat. Rev. Drug Discov. 2014, 13:465-476.
25. Ohashi K., et al. Role of anti-inflammatory adipokines in obesity-related diseases. Trends Endocrinol. Metab. 2014, 25:348-355.
26. Samuel V.T., Shulman G.I. Mechanisms for insulin resistance: common threads and missing links. Cell 2012, 148:852-871.
27. Samuel V.T., et al. Lipid-induced insulin resistance: unravelling the mechanism. Lancet 2010, 375:2267-2277.
28. Hocking S., et al. Adiposity and insulin resistance in humans: the role of the different tissue and cellular lipid depots. Endocr. Rev. 2013, 34:463-500.
29. Neeland I.J., et al. Dysfunctional adiposity and the risk of prediabetes and type 2 diabetes in obese adults. JAMA 2012, 308:1150-1159.
30. Gesta S., et al. Developmental origin of fat: tracking obesity to its source. Cell 2007, 131:242-256.
31. Tchkonia T., et al. Mechanisms and metabolic implications of regional differences among fat depots. Cell Metab. 2013, 17:644-656.
32. Bjorntorp P. 'Portal' adipose tissue as a generator of risk factors for cardiovascular disease and diabetes. Arteriosclerosis 1990, 10:493-496.
33. Lafontan M., Girard J. Impact of visceral adipose tissue on liver metabolism. Part I: heterogeneity of adipose tissue and functional properties of visceral adipose tissue. Diabetes Metab. 2008, 34:317-327.
34. Hansen I., et al. Insulin resistance in acromegaly: defects in both hepatic and extrahepatic insulin action. Am. J. Physiol. 1986, 250:E269-E273.
35. Karlander S., et al. Increased glucose turnover and glucose cycling in acromegalic patients with normal glucose tolerance. Diabetologia 1986, 29:778-783.
36. Foss M.C., et al. Peripheral glucose metabolism in acromegaly. J. Clin. Endocrinol. Metab. 1991, 72:1048-1053.
37. Bolinder J., et al. Insulin action in human adipose tissue in acromegaly. J. Clin. Investig. 1986, 77:1201-1206.
38. Nielsen S., et al. Pharmacological antilipolysis restores insulin sensitivity during growth hormone exposure. Diabetes 2001, 50:2301-2308.
39. Nielsen T.S., et al. Dissecting adipose tissue lipolysis: molecular regulation and implications for metabolic disease. J. Mol. Endocrinol. 2014, 52:R199-R222.
40. Yin D., et al. Somatotropin-dependent decrease in fatty acid synthase mRNA abundance in 3T3-F442A adipocytes is the result of a decrease in both gene transcription and mRNA stability. Biochem. J. 1998, 331:815-820.
41. Ottosson M., et al. Growth hormone inhibits lipoprotein lipase activity in human adipose tissue. J. Clin. Endocrinol. Metab. 1995, 80:936-941.
42. Clasen B.F., et al. Gene expression in skeletal muscle after an acute intravenous GH bolus in human subjects: identification of a mechanism regulating ANGPTL4. J. Lipid Res. 2013, 54:1988-1997.
43. Boero L., et al. GH levels and insulin sensitivity are differently associated with biomarkers of cardiovascular disease in active acromegaly. Clin. Endocrinol. 2012, 77:579-585.
44. Moller N., et al. Basal- and insulin-stimulated substrate metabolism in patients with active acromegaly before and after adenomectomy. J. Clin. Endocrinol. Metab. 1992, 74:1012-1019.
45. Higham C.E., et al. Pegvisomant improves insulin sensitivity and reduces overnight free fatty acid concentrations in patients with acromegaly. J. Clin. Endocrinol. Metab. 2009, 94:2459-2463.
46. Nellemann B., et al. Growth hormone-induced insulin resistance in human subjects involves reduced pyruvate dehydrogenase activity. Acta Physiol. 2014, 210:392-402.
47. Ueland T., et al. Associations between body composition, circulating interleukin-1 receptor antagonist, osteocalcin, and insulin metabolism in active acromegaly. J. Clin. Endocrinol. Metab. 2010, 95:361-368.
48. Olarescu N.C., et al. Inflammatory adipokines contribute to insulin resistance in active acromegaly and respond differently to different treatment modalities. Eur. J. Endocrinol. 2014, 170:39-48.
49. Olarescu N.C., et al. The metabolic risk in newly diagnosed patients with acromegaly is related to fat distribution and circulating adipokines and improves after treatment. Neuroendocrinology 2015, Published online January 9, 2015. 10.1159/000371818.
50. Freda P.U., et al. Lower visceral and subcutaneous but higher intermuscular adipose tissue depots in patients with growth hormone and insulin-like growth factor I excess due to acromegaly. J. Clin. Endocrinol. Metab. 2008, 93:2334-2343.
51. Reyes-Vidal C., et al. Prospective study of surgical treatment of acromegaly: effects on ghrelin, weight, adiposity, and markers of CV risk. J. Clin. Endocrinol. Metab. 2014, 99:4124-4132.
52. Reyes-Vidal C.M., et al. Adipose tissue redistribution and ectopic lipid deposition in active acromegaly and effects of surgical treatment. J. Clin. Endocrinol. Metab. 2015, 100:2946-2955.
53. Barclay J.L., et al. GH-dependent STAT5 signaling plays an important role in hepatic lipid metabolism. Endocrinology 2011, 152:181-192.
54. Cordoba-Chacon J., et al. Growth hormone inhibits hepatic de novo lipogenesis in adult mice. Diabetes 2015, 64:3093-3103.
55. Winhofer Y., et al. No evidence of ectopic lipid accumulation in the pathophysiology of the acromegalic cardiomyopathy. J. Clin. Endocrinol. Metab. 2014, 99:4299-4306.
56. Madsen M., et al. Fat content in liver and skeletal muscle changes in a reciprocal manner in patients with acromegaly during combination therapy with a somatostatin analog and a GH receptor antagonist: a randomized clinical trial. J. Clin. Endocrinol. Metab. 2012, 97:1227-1235.
57. Olarescu N.C., et al. GH action influences adipogenesis of mouse adipose tissue-derived mesenchymal stem cells. J. Endocrinol. 2015, 226:13-23.
58. Wabitsch M., et al. Mitogenic and antiadipogenic properties of human growth hormone in differentiating human adipocyte precursor cells in primary culture. Pediatr. Res. 1996, 40:450-456.
59. Lu C., et al. A novel effect of growth hormone on macrophage modulates macrophage-dependent adipocyte differentiation. Endocrinology 2010, 151:2189-2199.
60. Berryman D.E., et al. Growth hormone and adipose tissue: beyond the adipocyte. Growth Horm. IGF Res. 2011, 21:113-123.
61. Benencia F., et al. Male bovine GH transgenic mice have decreased adiposity with an adipose depot-specific increase in immune cell populations. Endocrinology 2015, 156:1794-1803.
62. Ciresi A., et al. Visceral adiposity index is associated with insulin sensitivity and adipocytokine levels in newly diagnosed acromegalic patients. J. Clin. Endocrinol. Metab. 2012, 97:2907-2915.
63. Lam K.S., et al. Serum adiponectin is reduced in acromegaly and normalized after correction of growth hormone excess. J. Clin. Endocrinol. Metab. 2004, 89:5448-5453.
64. Silha J.V., et al. Perturbations in adiponectin, leptin and resistin levels in acromegaly: lack of correlation with insulin resistance. Clin. Endocrinol. 2003, 58:736-742.
65. White U.A., et al. The modulation of adiponectin by STAT5-activating hormones. Am. J. Physiol. Endocrinol. Metab. 2016, 310:E129-E136.
66. Ciresi A., et al. Serum visfatin levels in acromegaly: Correlation with disease activity and metabolic alterations. Growth Horm. IGF Res. 2015, 25:240-246.
67. Liu T.F., et al. NAD+-dependent sirtuin 1 and 6 proteins coordinate a switch from glucose to fatty acid oxidation during the acute inflammatory response. J. Biol. Chem. 2012, 287:25758-25769.
68. Froy O. Metabolism and circadian rhythms--implications for obesity. Endocr. Rev. 2010, 31:1-24.
69. Brooks A.J., et al. Mechanism of activation of protein kinase JAK2 by the growth hormone receptor. Science 2014, 344:1249783.
70. Dominici F.P., et al. Influence of the crosstalk between growth hormone and insulin signalling on the modulation of insulin sensitivity. Growth Horm. IGF Res. 2005, 15:324-336.
71. Brooks A.J., Waters M.J. The growth hormone receptor: mechanism of activation and clinical implications. Nat. Rev. Endocrinol. 2010, 6:515-525.
72. Feng X., et al. Suppressors of cytokine signaling (SOCS) and type 2 diabetes. Mol. Biol. Rep. 2014, 41:2265-2274.
73. del Rincon J.P., et al. Growth hormone regulation of p85alpha expression and phosphoinositide 3-kinase activity in adipose tissue: mechanism for growth hormone-mediated insulin resistance. Diabetes 2007, 56:1638-1646.
74. Takano A., et al. Growth hormone induces cellular insulin resistance by uncoupling phosphatidylinositol 3-kinase and its downstream signals in 3T3-L1 adipocytes. Diabetes 2001, 50:1891-1900.
75. Jessen N., et al. Evidence against a role for insulin-signaling proteins PI 3-kinase and Akt in insulin resistance in human skeletal muscle induced by short-term GH infusion. Am. J. Physiol. Endocrinol. Metab. 2005, 288:E194-E199.
76. Henry R.R., et al. Hyperglycemia associated with pasireotide: results from a mechanistic study in healthy volunteers. J. Clin. Endocrinol. Metab. 2013, 98:3446-3453.
77. Tzanela M., et al. Glucose homeostasis in patients with acromegaly treated with surgery or somatostatin analogues. Clin. Endocrinol. 2011, 75:96-102.
78. Steffin B., et al. Effects of the long-acting somatostatin analogue Lanreotide Autogel on glucose tolerance and insulin resistance in acromegaly. Eur. J. Endocrinol. 2006, 155:73-78.
79. Shishko P.I., et al. Insulin-like growth factors and binding proteins in patients with recent-onset type 1 (insulin-dependent) diabetes mellitus: influence of diabetes control and intraportal insulin infusion. Diabetes Res. Clin. Pract. 1994, 25:1-12.
80. Leung K.C., et al. Insulin regulation of human hepatic growth hormone receptors: divergent effects on biosynthesis and surface translocation. J. Clin. Endocrinol. Metab. 2000, 85:4712-4720.
81. Samson S.L. Pasireotide in acromegaly: an overview of current mechanistic and clinical data. Neuroendocrinology 2015, 102:8-17.
82. Lindberg-Larsen R., et al. The impact of pegvisomant treatment on substrate metabolism and insulin sensitivity in patients with acromegaly. J. Clin. Endocrinol. Metab. 2007, 92:1724-1728.
83. Neggers S.J., et al. Hypothesis: extra-hepatic acromegaly: a new paradigm?. Eur. J. Endocrinol. 2011, 164:11-16.
84. Brummer R.J., et al. Adipose tissue and muscle volume determination by computed tomography in acromegaly, before and 1 year after adenomectomy. Eur. J. Clin. Investig. 1993, 23:199-205.
85. Hansen T.B., et al. Body composition in active acromegaly during treatment with octreotide: a double-blind, placebo-controlled cross-over study. Clin. Endocrinol. 1994, 41:323-329.
86. O'Sullivan A.J., et al. Body composition and energy expenditure in acromegaly. J. Clin. Endocrinol. Metab. 1994, 78:381-386.
87. Plockinger U., Reuter T. Pegvisomant increases intra-abdominal fat in patients with acromegaly: a pilot study. Eur. J. Endocrinol. 2008, 158:467-471.